NPHLA Tracker · Clinical trials (ClinicalTrials.gov)
Clinical Trial Tracker: Metabolic & Aesthetic Medicine
Clinical trials followed in metabolic and aesthetic medicine — obesity and incretin therapies, neurotoxins, dermal fillers, regenerative treatments and hair restoration — with each study’s status, phase and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 300
- Changed in 7 days
- 7
- Latest record
- Jurisdiction
- International / multiple
Records
300 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| AMAZE 8: AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: NNC0487-0111; Semaglutide; Placebo (matched to NNC0487-0111); Placebo (matched to semaglutide) | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07400107 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-8: A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719Conditions: Obesity; Overweight. Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07232719 (opens in a new tab)Primary source | System checked NPHLA updated |
| BioM: Biological Profiles of Neuropeptides, Neurotrophins and miRNA in MigraineNCT07832032Changed in the last 7 days Status changed from “Not yet recruiting” to “Enrolling by invitation” · Conditions: Migraine. Interventions: Rimegepant 75 MG | Enrolling by invitation | Phase not stated | Nordlandssykehuset HF | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07832032 (opens in a new tab)Primary source | System checked NPHLA updated |
| CITTE: Comparing Injection Treatments for Tennis ElbowNCT03984955Conditions: Tennis Elbow; Lateral Epicondylitis; Elbows Tendonitis. Interventions: Sodium hyaluronate with mannitol (Ostenil Tendon); Platelet-Rich Plasma Injection; Subcutaneous sham injection | Recruiting | Not applicable | Wrightington, Wigan and Leigh NHS Foundation Trust | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03984955 (opens in a new tab)Primary source | System checked NPHLA updated |
| PRE-CARE-DIET: Precision Nutrition to Improve Cardiometabolic Health With Dietary (Poly)PhenolsNCT06347094Conditions: Individual Variability in (Poly)Phenol Metabolism; Cardiometabolic Health; Personalized Dietary Intervention; Obesity. Interventions: Personalized Dietary Plan; Oral (Poly)phenol Challenge Test (OPCT); General Dietary Advice | Recruiting | Not applicable | University of Parma | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06347094 (opens in a new tab)Primary source | System checked NPHLA updated |
| Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.NCT07391267Conditions: Chronic Kidney Diseases; MAFLD. Interventions: Semaglutide Oral Tablet; Placebo; Standard medical treatment | Recruiting | Not applicable | Institute of Liver and Biliary Sciences, India | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07391267 (opens in a new tab)Primary source | System checked NPHLA updated |
| GLP1: Semaglutide in Youth With Autism Spectrum DisorderNCT07770152Conditions: Autism Spectrum Disorder; Obesity. Interventions: Glucagon-like peptide-1 receptor agonist：Semaglutide; Lifestyle Management (LSM) Counseling | Recruiting | Phase 4 | Children's Hospital Medical Center, Cincinnati | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07770152 (opens in a new tab)Primary source | System checked NPHLA updated |
| COMPACT: Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 DiabetesNCT07926152Conditions: Type 2 Diabetes (T2DM); Obesity & Overweight; Sarcopenia. Interventions: Supervised exercise training; protein supplement; Standardized lifestyle counseling | Not yet recruiting | Not applicable | German Diabetes Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07926152 (opens in a new tab)Primary source | System checked NPHLA updated |
| SERINITY: A Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5NCT07924267Conditions: Obesity & Overweight; Overweight (BMI > 30). Interventions: NKS-3; NKS-5 | Completed | Phase 1 | EktaH | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07924267 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 DiabetesNCT07924553Conditions: Type 1 Diabetes. Interventions: Mazdutide; Placbo | Not yet recruiting | Not applicable | Peking University People's Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07924553 (opens in a new tab)Primary source | System checked NPHLA updated |
| Ocular Changes in Patients Using Tirzepatide or SemaglutideNCT07924618Conditions: Type 2 Diabetes Mellitus; Obesity. Interventions: Semaglutide; Tirzepatide | Recruiting | Phase not stated | Istanbul University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07924618 (opens in a new tab)Primary source | System checked NPHLA updated |
| Enith1: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045Conditions: Obesity or Overweight. Interventions: Placebo; Enicepatide | Recruiting | Phase 3 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07351045 (opens in a new tab)Primary source | System checked NPHLA updated |
| Enith2: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058Conditions: Obesity or Overweight; Type 2 Diabetes Mellitus. Interventions: Placebo; Enicepatide | Recruiting | Phase 3 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07351058 (opens in a new tab)Primary source | System checked NPHLA updated |
| Elecoglipron: A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusNCT07775404Conditions: Obesity; Overweight. Interventions: Elecoglipron; Placebo | Recruiting | Phase 3 | AstraZeneca | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07775404 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151Changed in the last 7 days Results first posted on ClinicalTrials.gov (2026-11-09) · Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Interventions: Retatrutide; Placebo | Completed | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05936151 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy and Safety of Two Hair Supplements in Men With Androgenic AlopeciaNCT07806474Changed in the last 7 days Status changed from “Not yet recruiting” to “Recruiting” · Conditions: Androgenic Alopecia; Healthy Adult Male. Interventions: formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast; formulation of grape seed extr… | Recruiting | Not applicable | Activ'inside | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07806474 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes MellitusNCT07923357Conditions: Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes; T2DM. Interventions: SAL0150 dose 1; SAL0150 dose 2; SAL0150 dose 2; SAL0150 dose 3; SAL0150 dose 3; Placebo; Semaglutide inject 1.0 mg | Not yet recruiting | Phase 2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07923357 (opens in a new tab)Primary source | System checked NPHLA updated |
| VITAL-H: Validation & Intervention Testing for Aging, Longevity and HealthspanNCT07923630Conditions: Aging; Functional Decline. Interventions: Dapagliflozin 10Mg Oral Tablet; Semaglutide oral; Placebo | Not yet recruiting | Phase 2 | The University of Texas Health Science Center at San Antonio | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07923630 (opens in a new tab)Primary source | System checked NPHLA updated |
| MINORA-MEN: Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.NCT07529977Conditions: Androgenetic Alopecia; Androgenetic Alopecia (AGA). Interventions: Minoxidil oral solution; Placebo oral solution | Not yet recruiting | Phase 3 | Eurofarma Laboratorios S.A. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07529977 (opens in a new tab)Primary source | System checked NPHLA updated |
| toxin: Can TrenibotulinumtoxinE Reverse OnabotulinumtoxinA Effect in Treating Lateral Canthal Lines?NCT07923448Conditions: Wrinkles and Rhytides. Interventions: TrenibotulinumtoxinE and OnabotulinumtoxinA; Onabotulinumtoxin A followed by placebo | Not yet recruiting | Phase 2 | Project Skin MD | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07923448 (opens in a new tab)Primary source | System checked NPHLA updated |
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseNCT07651319Conditions: Alzheimer Dementia (AD). Interventions: IL-2 (Aldesleukin); Semaglutide Plus IL-2; Placebo | Recruiting | Phase 1 / Phase 2 | The Methodist Hospital Research Institute | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07651319 (opens in a new tab)Primary source | System checked NPHLA updated |
| QUEST: Lifestyle Counseling and Medication for Adolescent Weight ManagementNCT04873245Conditions: Obesity, Childhood. Interventions: Intensive Behavioral Program; Semaglutide and Behavioral Program | Completed | Phase 2 | University of Minnesota | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04873245 (opens in a new tab)Primary source | System checked NPHLA updated |
| AWAKENING: Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic AlopeciaNCT07907783Conditions: Androgenetic Alopecia. Interventions: PP405 0.05% Topical Gel; Vehicle Topical Gel | Not yet recruiting | Phase 2 | Pelage Pharmaceuticals, Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07907783 (opens in a new tab)Primary source | System checked NPHLA updated |
| GLP-BARI-VAN: Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With ObesityNCT07901777Conditions: Obesity & Overweight. Interventions: GLP-1 Receptor Agonist Therapy; Laparoscopic Sleeve Gastrectomy | Recruiting | Phase not stated | Yuzuncu Yil University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07901777 (opens in a new tab)Primary source | System checked NPHLA updated |
| MEASURE: Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)NCT07639684Conditions: Type 2 Diabetes Mellitus (T2D); Obesity (BMI>30). Interventions: ESG with OverStitch | Not yet recruiting | Not applicable | Boston Scientific Corporation | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07639684 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399Conditions: Obesity or Overweight. Interventions: Maridebart Cafraglutide | Recruiting | Phase 3 | Amgen | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07575399 (opens in a new tab)Primary source | System checked NPHLA updated |
| PLATINUM EU: A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)NCT07210463Conditions: Neuromuscular Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Acetylcholine Release Inhibitors; Membrane Transpor…. Interventions: NT 201; NT 201 Placebo | Active, not recruiting | Phase 3 | Merz Aesthetics GmbH | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07210463 (opens in a new tab)Primary source | System checked NPHLA updated |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesNCT07685808Conditions: Overweight or Obesity. Interventions: Olatorepatide; Placebo | Recruiting | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07685808 (opens in a new tab)Primary source | System checked NPHLA updated |
| T2DM: UBT251 Injection Phase II (Type 2 Diabetes Mellitus) StudyNCT07163624Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: UBT251 Injection 2.0 mg and UBT251 Injection Placebo; UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo;… | Completed | Phase 2 | The United Bio-Technology (Hengqin) Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07163624 (opens in a new tab)Primary source | System checked NPHLA updated |
| SPOT-DM: Semaglutide for the Prevention Of Post-Transplant Diabetes MellitusNCT06913023Conditions: Kidney Transplant Recipient. Interventions: Semaglutide 0.25 mg; Semaglutide 0.5 mg; Semaglutide 1.0 mg; Semaglutide 1.7mg subcutaneous; Semaglutide 2.4 MG/0.75 ML… | Not yet recruiting | Phase 2 / Phase 3 | University Health Network, Toronto | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06913023 (opens in a new tab)Primary source | System checked NPHLA updated |
| Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris.NCT07919886Conditions: Acne; Acne Papulopustulosa. Interventions: Fractional co2 laser; Botulinium Toxin-A | Not yet recruiting | Phase 3 | Cairo University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07919886 (opens in a new tab)Primary source | System checked NPHLA updated |
| Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic AlopeciaNCT03474718Conditions: Androgenic Alopecia. Interventions: Platelet-rich Plasma Left Side; Platelet-rich Plasma Right Side | Not yet recruiting | Early phase 1 | Wake Forest University Health Sciences | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03474718 (opens in a new tab)Primary source | System checked NPHLA updated |
| Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in DiabeticsNCT05243368Conditions: Foot, Diabetic. Interventions: Personalized Nutritional Intervention | Active, not recruiting | Not applicable | Maimónides Biomedical Research Institute of Córdoba | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05243368 (opens in a new tab)Primary source | System checked NPHLA updated |
| RHA®4 for Midface Volume DeficiencyNCT05133739Conditions: Cheek Augmentation; Correction of Age-related Midface Contour Deficiencies. Interventions: injection of RHA®4 in Midface; injection of Comparator Product in Midface | Completed | Phase not stated | Teoxane SA | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05133739 (opens in a new tab)Primary source | System checked NPHLA updated |
| Volido PAS: Post-Approval Study of Saypha® ChIQ™ for Midface Augmentation in Subjects With Fitzpatrick Skin Types V and VINCT07918443Conditions: Moderate to Severe Midface Volume Deficit. Interventions: Crosslinked hyaluronic acid dermal filler with lidocaine | Not yet recruiting | Not applicable | Croma-Pharma GmbH | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07918443 (opens in a new tab)Primary source | System checked NPHLA updated |
| Exosomes for Striae DistensaeNCT07919964Conditions: Striae Distensae. Interventions: Micro needling then exosome application topically; Micro needling | Completed | Not applicable | Tanta University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07919964 (opens in a new tab)Primary source | System checked NPHLA updated |
| REDEFINE: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityNCT07919405Conditions: Hypertension; Obesity. Interventions: CagriSema; Semaglutide; Cagrilintide; Placebo | Not yet recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07919405 (opens in a new tab)Primary source | System checked NPHLA updated |
| The Effect of Different Diets on Arterial Stiffness in Obese Patients on SemaglutideNCT04990024Conditions: Obesity; Weight Loss. Interventions: Dietary Intervention Med Diet; Dietary Intervention HP/LC Diet | Completed | Not applicable | American University of Beirut Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04990024 (opens in a new tab)Primary source | System checked NPHLA updated |
| Enith-MACE: A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular DiseaseNCT07918846Conditions: Overweight; Obesity; Cardiovascular Disease. Interventions: Enicepatide; Placebo | Not yet recruiting | Phase 3 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07918846 (opens in a new tab)Primary source | System checked NPHLA updated |
| VESPER-3: A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or OverweightNCT06973720Conditions: Obesity; Overweight or Obesity. Interventions: MET097; Placebo | Completed | Phase 2 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06973720 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)NCT07919678Conditions: Obesity; Overweight; Osteoarthritis of the Knee. Interventions: Berobenatide; Placebo | Recruiting | Phase 3 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07919678 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Multidisciplinary Weight Loss Program at AUB-MCNCT04194424Conditions: Obesity; Weight Loss. Interventions: Multidisciplinary weight loss program; Standard Care; Metformin Hcl 850Mg Tab | Active, not recruiting | Not applicable | American University of Beirut Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04194424 (opens in a new tab)Primary source | System checked NPHLA updated |
| Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled TrialNCT07111494Conditions: Psoriatic Arthritis (PsA). Interventions: GLP-1 agonists; Nutrition Counseling | Recruiting | Phase 4 | Medical College of Wisconsin | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07111494 (opens in a new tab)Primary source | System checked NPHLA updated |
| Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 DiabetesNCT06593314Conditions: Heart Failure; Diabetes. Interventions: Message with EchoGo; Standard Message | Recruiting | Not applicable | University of Texas Southwestern Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06593314 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial LinesNCT07871513Conditions: Upper Facial Lines; Glabellar Lines. Interventions: TrenibotulinumtoxinE and OnabotulinumtoxinA; Placebo; OnabotulinumtoxinA | Recruiting | Phase 2 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07871513 (opens in a new tab)Primary source | System checked NPHLA updated |
| MARITIME-T2D-3: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNCT07866066Conditions: Diabetes Mellitus, Type 2. Interventions: Maridebart cafraglutide; Semaglutide | Recruiting | Phase 3 | Amgen | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07866066 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416Conditions: Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM). Interventions: Enicepatide; Placebo | Recruiting | Phase 3 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07670416 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-PEDS: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336Conditions: Diabetes Mellitus, Type 2. Interventions: Orforglipron; Dulaglutide | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07668336 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07794579 (opens in a new tab)Primary source | System checked NPHLA updated |
| SOLIS-1: A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932Conditions: Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseas…. Interventions: PF-08653945; PF-08653944; Placebo | Active, not recruiting | Phase 2 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07575932 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) for two broad searches — obesity and incretin therapies, and aesthetic and regenerative medicine (botulinum toxin, dermal fillers, polynucleotides, exosomes, platelet-rich plasma) — and for every topic with a trial query, on the schedule set in the Source Registry. Each study is stored with its registry fields as published. Changes in overall status and newly posted results are recorded with the date the pipeline detected them.
This tracker lists every tracked study whose last registry update falls within the past 365 days, newest first. Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch dated within the last 365 days.
What does it cover?
Studies on ClinicalTrials.gov — from the United States and other countries — that match the configured searches, from the date tracking began. Studies registered elsewhere, described with other terms, or not updated in the last year are not included.
What are its limitations?
Registry data is supplied by sponsors and may be incomplete or out of date. Inclusion reflects search terms, not clinical importance. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.